bb3dc2ff-a686-483e-8d3c-e06649462881
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- MYOGENESIS+0.460
- COAGULATION+0.380
- APICAL_JUNCTION+0.350
- ANGIOGENESIS+0.340
- HEDGEHOG_SIGNALING+0.330
- NOTCH_SIGNALING+0.320
- WNT_BETA_CATENIN_SIGNALING+0.300
- KRAS_SIGNALING_DN+0.240
- XENOBIOTIC_METABOLISM+0.230
Top 10 suppressed
- E2F_TARGETS-0.430
- G2M_CHECKPOINT-0.410
- PROTEIN_SECRETION-0.330
- ANDROGEN_RESPONSE-0.320
- MITOTIC_SPINDLE-0.220
- MTORC1_SIGNALING-0.110
- MYC_TARGETS_V1-0.110
- PI3K_AKT_MTOR_SIGNALING-0.100
- UNFOLDED_PROTEIN_RESPONSE-0.080
- UV_RESPONSE_DN-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d496ef4f-4716-4e6e-94e3-fce93b26d4ee | — | — | 0.919 |
| 2 | 1652b0a3-dc1d-4490-9632-07673713deb1 | — | — | 0.909 |
| 3 | b9189c77-004e-461a-9c15-b504b12a3030 | — | — | 0.880 |
| 4 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.874 |
| 5 | 6bc70f5c-fdba-4bef-865a-793b7782a107 | — | — | 0.868 |
| 6 | SAMN03290910 | — | — | 0.863 |
| 7 | 9b308588-5e79-46ab-b186-6edd686695c6 | — | — | 0.862 |
| 8 | 05167d53-0b47-4131-bfa4-450b236b9fd5 | — | — | 0.857 |
| 9 | a4322796-9189-48c2-9e7c-7b1493b5799a | — | — | 0.842 |
| 10 | 45b4921e-fce7-41f8-bb63-ed98343ceec8 | — | — | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| MYOGENESIS | 0.460 | Inavolisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |